DK1051500T3 - Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme - Google Patents

Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme

Info

Publication number
DK1051500T3
DK1051500T3 DK99905450T DK99905450T DK1051500T3 DK 1051500 T3 DK1051500 T3 DK 1051500T3 DK 99905450 T DK99905450 T DK 99905450T DK 99905450 T DK99905450 T DK 99905450T DK 1051500 T3 DK1051500 T3 DK 1051500T3
Authority
DK
Denmark
Prior art keywords
aur1
aur2
polypeptides
diagnosis
treatment
Prior art date
Application number
DK99905450T
Other languages
Danish (da)
English (en)
Inventor
Gregory D Plowman
Kevin Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK1051500T3 publication Critical patent/DK1051500T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99905450T 1998-01-22 1999-01-21 Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme DK1051500T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/012,135 US6716575B2 (en) 1995-12-18 1998-01-22 Diagnosis and treatment of AUR1 and/or AUR2 related disorders
PCT/US1999/001283 WO1999037788A2 (en) 1998-01-22 1999-01-21 Diagnosis and treatment of aur1 and/or aur2 related disorders

Publications (1)

Publication Number Publication Date
DK1051500T3 true DK1051500T3 (da) 2005-12-19

Family

ID=21753554

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99905450T DK1051500T3 (da) 1998-01-22 1999-01-21 Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme

Country Status (11)

Country Link
US (3) US6716575B2 (de)
EP (1) EP1051500B1 (de)
JP (1) JP2002508937A (de)
AT (1) ATE302278T1 (de)
AU (1) AU2560599A (de)
CA (1) CA2318352A1 (de)
CY (1) CY1105446T1 (de)
DE (1) DE69926731T2 (de)
DK (1) DK1051500T3 (de)
ES (1) ES2247783T3 (de)
WO (1) WO1999037788A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999010498A2 (en) 1997-08-27 1999-03-04 Pioneer Hi-Bred International, Inc. Genes encoding enzymes for lignin biosynthesis and uses thereof
WO2000061744A1 (fr) 1999-04-09 2000-10-19 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux genes de foetus
ATE394102T1 (de) * 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
EP1317450B1 (de) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als protein-kinasehemmer
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
WO2002062989A2 (en) * 2001-02-08 2002-08-15 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
EP2213737B1 (de) 2002-02-01 2012-11-07 Life Technologies Corporation Doppelsträngige Oligonukleotide
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1472245A2 (de) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Heteroaryl-verbindungen und ihre anwendung als gsk-3-hemmer
AU2003218215A1 (en) * 2002-03-15 2003-09-29 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
EP1492871A2 (de) * 2002-03-28 2005-01-05 QLT Inc. Mit krebs assoziierte proteinkinasen und deren verwendung
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DK1532145T3 (da) 2002-08-02 2007-01-15 Vertex Pharma Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
ATE494296T1 (de) * 2002-09-11 2011-01-15 Genentech Inc Zusammensetzungen und verfahren für die tumordiagnose und behandlung
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
EP2305812A3 (de) * 2002-11-14 2012-06-06 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7612196B2 (en) * 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
ES2290529T3 (es) 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
EP1636380A2 (de) * 2003-05-30 2006-03-22 Genomic Health, Inc. Genexpressionsmarker zur reaktion auf egfr-inhibitor-arzneistoffe
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
AU2004297235A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
CA2551267C (en) * 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1756308A1 (de) * 2004-04-23 2007-02-28 Exagen Diagnostics, Inc. Zusammensetzungen und verfahren zur brustkrebsprognose
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
EP1763514A2 (de) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl-substituierte pyrimidindiaminverbindungen und deren verwendung
WO2006031273A2 (en) * 2004-06-18 2006-03-23 Cytokinetics, Inc. Cellular phenotype
EP1778669A2 (de) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase-inhibitoren
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
EP1813609B1 (de) * 2004-10-29 2013-06-19 Msd K.K. Neue aminopyridinderivate mit selektiva aurora-a-hemmender wirkung
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1815014B1 (de) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス, インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
US20060142247A1 (en) * 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
JP2008533181A (ja) * 2005-04-14 2008-08-21 エフ.ホフマン−ラ ロシュ アーゲー 三環式アゾール誘導体、それらの製造及び医薬品としての使用
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
CA2601869A1 (en) * 2005-08-12 2007-02-22 Astellas Pharma Inc. Method for identifying target protein of agent and method for screening therapeutic agent for diabetes using target protein
AU2006279376B2 (en) * 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
WO2007030795A2 (en) * 2005-09-09 2007-03-15 Cytokinetics, Inc. Cellular phenotype
CA2622352C (en) * 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1954277B1 (de) * 2005-11-03 2017-01-18 Vertex Pharmaceuticals Incorporated Als kinaseinhibitoren geeignete aminopyrimidine
BRPI0708850A2 (pt) * 2006-03-20 2011-06-21 Hoffmann La Roche derivados de ftalazinona pirazol, sua produção e uso como agentes farmacêuticos
MX2008011860A (es) * 2006-03-23 2008-09-30 Hoffmann La Roche Derivados de indazol substituidos, su manufactura y uso como agentes farmaceuticos.
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
MX2009004807A (es) * 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
NZ577768A (en) * 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
MX2009009592A (es) * 2007-03-09 2009-11-10 Vertex Pharma Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009009590A (es) * 2007-03-09 2009-11-10 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
ATE526328T1 (de) * 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
AU2008247592A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
CN101679387A (zh) * 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
JP5389786B2 (ja) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
MX2009012719A (es) * 2007-05-24 2010-02-04 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CN101790532B (zh) * 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3,4-b]吡啶-3-胺及其衍生物的制备方法
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
DE3069468D1 (en) 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co., Madison Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (de) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclische polyhydroxy tyrosin-kinase-inhibitoren
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5958721A (en) 1993-04-07 1999-09-28 Cancer Research Campaign Technology, Ltd. Methods for screening of substances for therapeutic activity and yeast for use therein
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5830648A (en) 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging
EP1655369A1 (de) 1995-12-18 2006-05-10 Sugen, Inc. Diagnose und Behandlung von mit AUR-1 und/oder AUR-2 assoziierten Krankeheiten

Also Published As

Publication number Publication date
US20050002938A1 (en) 2005-01-06
EP1051500A2 (de) 2000-11-15
CY1105446T1 (el) 2010-04-28
CA2318352A1 (en) 1999-07-29
US6207401B1 (en) 2001-03-27
US20020081578A1 (en) 2002-06-27
JP2002508937A (ja) 2002-03-26
WO1999037788A3 (en) 1999-09-30
WO1999037788A9 (en) 1999-11-04
EP1051500B1 (de) 2005-08-17
US6716575B2 (en) 2004-04-06
WO1999037788A2 (en) 1999-07-29
DE69926731D1 (de) 2005-09-22
ES2247783T3 (es) 2006-03-01
ATE302278T1 (de) 2005-09-15
AU2560599A (en) 1999-08-09
DE69926731T2 (de) 2006-05-18
US6841579B1 (en) 2005-01-11

Similar Documents

Publication Publication Date Title
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
DE69932813D1 (de) Nukleinsäurebindungsproteine
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE532533T1 (de) Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
DE69033128D1 (de) Für leberzellkarzinom spezifisches onkogen
FI885312L (fi) Menetelmä spesifisesti sitovan proteiinin ja vastaavan sidottavan aineen välisen reaktion yhden tai useamman komponentin määrittämiseksi koenäytteestä käyttäen ainakin yhtä leimattua komponenttia, menetelmä leimatun komponentin valmistamiseksi sekä koepakkaus.......
WO2003020005A3 (en) Lp mammalian proteins; related reagents
DE69731964D1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
ATE294237T1 (de) S?ugetier thymokingene
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
EP1572931A4 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
WO2002074906A3 (en) Lp mammalian proteins; related reagents
KR880701886A (ko) 췌장효소원의 유리활성화 펩티드의 면역검정에 의한 질병의 진단, 위중도 예견, 및 모니터링
DE69940812D1 (de) Mekk1 serin threonin kinasen -fha forkhead verbundenes bereich -interagierendes protein 1 (mif1)
WO2002063009A8 (en) Lp mammalian proteins; related reagents
NO20016340L (no) Hodetraumeindusert cytoplasmatisk kalsiumbindende protein
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.